GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » Revenue

Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Revenue : $2,187 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Swedish Orphan Biovitrum AB Revenue?

Swedish Orphan Biovitrum AB's revenue for the three months ended in Mar. 2024 was $601 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $2,187 Mil. Swedish Orphan Biovitrum AB's Revenue per Share for the three months ended in Mar. 2024 was $0.87. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $3.26.

Good Sign:

Swedish Orphan Biovitrum AB has shown predictable revenue and earnings growth.

During the past 12 months, the average Revenue per Share Growth Rate of Swedish Orphan Biovitrum AB was 12.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 11.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 13.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was 25.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Swedish Orphan Biovitrum AB's highest 3-Year average Revenue per Share Growth Rate was 40.90% per year. The lowest was -31.70% per year. And the median was 11.50% per year.


Swedish Orphan Biovitrum AB Revenue Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Revenue Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,510.54 1,824.80 1,708.44 1,810.56 2,156.74

Swedish Orphan Biovitrum AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 500.08 452.41 466.22 667.12 600.89

Competitive Comparison of Swedish Orphan Biovitrum AB's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Revenue distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Revenue falls into.



Swedish Orphan Biovitrum AB Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,187 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Swedish Orphan Biovitrum AB  (OTCPK:SWOBY) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Swedish Orphan Biovitrum AB Revenue Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).